EU migraine drug approval triggers multimillion-dollar bill for Lundbeck
When Lundbeck’s migraine treatment Vyepti was approved by the EU earlier this year, it passed a milestone – for Lundbeck itself, but also for investors in the drug’s original developer, who were now owed a total of USD 230m.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
More than two years after Lundbeck bought migraine drug Vyepti alongside the company behind it, Alder Biopharmaceuticals, which was publicly listed in the US before the acquisition, former investors can look forward to receiving the last bit of money they were promised.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck's migraine drug approved in EU
For subscribers
